Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
Crossref DOI link: https://doi.org/10.1007/s40258-016-0301-y
Published Online: 2017-01-06
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ericsson, Åsa
Lundqvist, Adam
Funding for this research was provided by:
Novo Nordisk
License valid from 2017-01-06